Setmelanotide Shows Promise in Hypothalamic Obesity ...Middle East

Treatment with setmelanotide, a melanocortin-4 receptor agonist, led to a significant reduction in BMI in a difficult-to-treat population of patients with hypothalamic obesity. Medscape Medical News

Hence then, the article about setmelanotide shows promise in hypothalamic obesity was published today ( Wednesday 15/05/2024 - 12:28 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Setmelanotide Shows Promise in Hypothalamic Obesity )

Also on site :

• UN welcomes ceasefire announced by Ukraine, Russia
• Not to be dramatic, but LEGO Batman: Legacy of the Dark Knight might be the best Batman game ever
• US greenlights bomb deal for Ukraine